Ascendis Pharma A/S vs PTC Therapeutics
ASND and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASND and PTCT compare
Ascendis Pharma A/S grew revenue faster over the last twelve months (113% versus −35.1% for PTC Therapeutics).
Ascendis Pharma A/S keeps more of each dollar of sales as profit, with a net margin of 70.8% compared with −9.2% at PTC Therapeutics.
Ascendis Pharma A/S scores higher on the StockData Score (7 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASND | PTCT |
|---|---|---|
| Size and price | ||
| Market cap | – | $5.0B |
| Share price | $251.27 | $59.97 |
| Change, 1 year | 22.1% | −11.0% |
| Change, 5 years | 56.4% | 45.2% |
| Beta (5Y) | 0.77 | 1.12 |
| Employees | 879 | 991 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 4.3× |
| EV/EBITDA | – | 16.4× |
| P/FCF | – | 2421× |
| FCF yield | – | 0.04% |
| Fair value | – | $46.85 |
| Margin of safety | – | −28.0% |
| Growth | ||
| Revenue growth (TTM) | 113% (better) | −35.1% |
| Revenue growth, 5Y average | 153% (better) | 35.4% |
| Net income growth (TTM) | – | −114% |
| EPS growth (TTM) | – | −114% |
| Profitability | ||
| Gross margin | 91.3% | – |
| Operating margin | 25.4% (better) | 12.8% |
| Net margin | 70.8% (better) | −9.2% |
| FCF margin | – | 0.18% |
| Financial health | ||
| Net debt / EBITDA | −1.61 | −7.63 |
| Interest coverage | 1.3× | – |
| Current ratio | 2.99 | 3.27 (better) |
| Altman Z-score | – | 0.77 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 120% |
| Held by insiders | 0.83% | 3.0% |
| Insider net buying, 12 months | −$4.7M (better) | −$55.5M |
| Short interest, % of float | – | 11.3% |
Go deeper
- ASND stock overview
- ASND income statement
- ASND valuation and score
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.